Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DVAX, GH, ITCI, IMVT, APLS, and represent 32.65% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: CYTK (+$88M), DVAX (+$67M), HRMY (+$50M), NMRA (+$47M), Septerna (+$44M), GPCR (+$43M), GMAB (+$42M), IMVT (+$41M), CLDX (+$39M), PTGX (+$39M).
- Started 15 new stock positions in RAPT, CLDX, Septerna, NVAX, XENE, RARE, GLPG, Upstream Bio, Onkure Therapeutics Inc-a, HRMY. BBIO, IMCR, PTGX, GMAB, SAVA.
- Reduced shares in these 10 stocks: ARGX (-$198M), VRNA (-$108M), NTLA (-$102M), , AXSM (-$95M), APGE (-$59M), TGTX (-$40M), KURA (-$38M), BCYC (-$32M), DYN (-$30M).
- Sold out of its positions in ALEC, ANRO, APGE, ARGX, RNA, AXSM, EDIT, FATE, NTLA, KURA. KYMR, MGX, PYXS, RLMD, SRRK, SLN, SYRS, TGTX, TVTX, VIGL, ALKS, PRTA.
- Deep Track Capital was a net seller of stock by $-337M.
- Deep Track Capital has $2.7B in assets under management (AUM), dropping by -14.96%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 62 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dynavax Technologies Corp Com New (DVAX) | 8.5 | $227M | +42% | 18M | 12.77 |
|
| Guardant Health (GH) | 7.3 | $196M | +6% | 6.4M | 30.55 |
|
| Intra Cellular Therapies (ITCI) | 6.2 | $167M | +24% | 2.0M | 83.52 |
|
| Immunovant (IMVT) | 5.5 | $149M | +38% | 6.0M | 24.77 |
|
| Apellis Pharmaceuticals (APLS) | 5.1 | $136M | -2% | 4.3M | 31.91 |
|
| Springworks Therapeutics (SWTX) | 4.7 | $125M | -9% | 3.5M | 36.13 |
|
| Cytokinetics Com New (CYTK) | 4.4 | $118M | +296% | 2.5M | 47.04 |
|
| Ocular Therapeutix (OCUL) | 4.1 | $110M | 13M | 8.54 |
|
|
| Miragen Therapeutics (VRDN) | 3.2 | $87M | +20% | 4.5M | 19.17 |
|
| Pliant Therapeutics (PLRX) | 2.9 | $79M | 6.0M | 13.17 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.8 | $76M | +129% | 2.8M | 27.12 |
|
| Ionis Pharmaceuticals (IONS) | 2.5 | $68M | -12% | 1.9M | 34.96 |
|
| Nurix Therapeutics (NRIX) | 2.1 | $57M | -22% | 3.0M | 18.84 |
|
| Mbx Biosciences (MBX) | 2.1 | $56M | 3.0M | 18.43 |
|
|
| Neumora Therapeutics Call Option (NMRA) | 2.1 | $55M | +593% | 5.2M | 10.60 |
|
| 89bio (ETNB) | 1.9 | $51M | +134% | 6.5M | 7.82 |
|
| Harmony Biosciences Hldgs In (HRMY) | 1.9 | $50M | NEW | 1.5M | 34.41 |
|
| Dyne Therapeutics (DYN) | 1.8 | $47M | -39% | 2.0M | 23.56 |
|
| Septerna | 1.6 | $44M | NEW | 1.9M | 22.90 |
|
| Genmab A/s Sponsored Ads (GMAB) | 1.6 | $42M | NEW | 2.0M | 20.87 |
|
| Akero Therapeutics (AKRO) | 1.5 | $42M | +116% | 1.5M | 27.82 |
|
| Verona Pharma Sponsored Ads (VRNA) | 1.5 | $40M | -73% | 850k | 46.44 |
|
| Celldex Therapeutics Com New (CLDX) | 1.5 | $39M | NEW | 1.5M | 25.27 |
|
| Protagonist Therapeutics (PTGX) | 1.4 | $39M | NEW | 1.0M | 38.60 |
|
| Biosante Pharmaceuticals (ANIP) | 1.3 | $36M | +28% | 649k | 55.28 |
|
| Bicara Therapeutics (BCAX) | 1.3 | $35M | +150% | 2.0M | 17.42 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.2 | $33M | -6% | 14M | 2.35 |
|
| Korro Bio (KRRO) | 1.2 | $33M | +2% | 875k | 38.07 |
|
| Terns Pharmaceuticals (TERN) | 1.2 | $31M | 5.6M | 5.54 |
|
|
| Engene Holdings (ENGN) | 1.1 | $30M | +74% | 4.6M | 6.65 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.0 | $28M | NEW | 654k | 42.07 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $26M | 3.6M | 7.32 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.8 | $23M | 1.4M | 16.75 |
|
|
| Bridgebio Pharma (BBIO) | 0.8 | $23M | NEW | 819k | 27.44 |
|
| Galapagos Nv Spon Adr (GLPG) | 0.8 | $22M | NEW | 781k | 27.50 |
|
| Olema Pharmaceuticals (OLMA) | 0.7 | $20M | -13% | 3.4M | 5.83 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.7 | $20M | -60% | 2.8M | 6.96 |
|
| Edgewise Therapeutics (EWTX) | 0.7 | $19M | -35% | 710k | 26.70 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.7 | $18M | -64% | 1.3M | 14.00 |
|
| Upstream Bio | 0.6 | $16M | NEW | 1.0M | 16.44 |
|
| Novavax Com New (NVAX) | 0.6 | $16M | NEW | 2.0M | 8.04 |
|
| Immunocore Hldgs Ads (IMCR) | 0.6 | $15M | NEW | 519k | 29.50 |
|
| Oruka Therapeutics (ORKA) | 0.5 | $15M | -39% | 750k | 19.39 |
|
| Geron Corporation (GERN) | 0.5 | $14M | -47% | 4.0M | 3.54 |
|
| Cybin Com New (CYBN) | 0.5 | $14M | 1.5M | 8.82 |
|
|
| Xencor (XNCR) | 0.4 | $12M | -37% | 500k | 22.98 |
|
| Aligos Therapeutics Com New (ALGS) | 0.4 | $9.7M | 244k | 39.84 |
|
|
| Rapt Therapeutics (RAPT) | 0.4 | $9.5M | NEW | 6.0M | 1.58 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $8.2M | 3.3M | 2.50 |
|
|
| Context Therapeutics (CNTX) | 0.3 | $7.8M | 7.4M | 1.05 |
|
|
| Allakos (ALLK) | 0.3 | $6.9M | +14% | 5.7M | 1.21 |
|
| Xenon Pharmaceuticals (XENE) | 0.2 | $6.6M | NEW | 169k | 39.20 |
|
| Avalo Therapeutics Com New (AVTX) | 0.2 | $6.4M | -10% | 867k | 7.43 |
|
| Inovio Pharmaceuticals Com Shs (INO) | 0.2 | $5.7M | +72% | 3.1M | 1.83 |
|
| Regulus Therapeutics (RGLS) | 0.2 | $5.2M | 3.3M | 1.58 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $5.1M | -78% | 219k | 23.28 |
|
| Adagio Therapeutics (IVVD) | 0.2 | $4.7M | -2% | 11M | 0.44 |
|
| Onkure Therapeutics Com Cl A | 0.2 | $4.5M | NEW | 524k | 8.60 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.1 | $3.4M | -85% | 610k | 5.57 |
|
| Eliem Therapeutics (CLYM) | 0.1 | $1.9M | -52% | 1.0M | 1.80 |
|
| Nektar Therapeutics (NKTR) | 0.1 | $1.8M | -87% | 2.0M | 0.93 |
|
| Cassava Sciences Put Option (SAVA) | 0.0 | $1.2M | NEW | 500k | 2.36 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2024 Q4 filed Feb. 14, 2025
- Deep Track Capital 2024 Q3 filed Nov. 14, 2024
- Deep Track Capital 2024 Q2 filed Aug. 14, 2024
- Deep Track Capital 2024 Q1 filed May 15, 2024
- Deep Track Capital 2023 Q4 filed Feb. 14, 2024
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022
- Deep Track Capital 2022 Q2 filed Aug. 12, 2022
- Deep Track Capital 2022 Q1 filed May 16, 2022
- Deep Track Capital 2021 Q4 filed Feb. 14, 2022